Overview

Glargine U300 Hospital Trial

Status:
Completed
Trial end date:
2019-03-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if treatment with Glargine U300 when compared to Glargine U100 will result in similar sugar control in patients with Type 2 Diabetes (T2D), who are admitted to the hospital and then transition at home, after discharge from the hospital.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Treatments:
Insulin
Insulin Glargine
Insulin glulisine
Insulin, Globin Zinc